The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is part of
the family of tyrosine kinase receptors. The binding of EGFR to its cognate ligands leads to …

Background In this study, our aim was to describe quality of life (QoL) prevalence and
heterogeneity in QoL reporting in colorectal cancer phase III trials. Methods We included all …

Abstract Purpose Inspired by the American Society of Clinical Oncology's recommendations
to strengthen the evidence base for older adults with cancer, the purpose of this systematic …

Background Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …

Colorectal cancer (CRC) is a public health problem: it is the third most common cancer in
men (746,000 new cases/year) and the second in women (614,000 new cases/year) …

Aim: To evaluate the incidence and risk of cardiac toxicities associated with panitumumab in
advanced cancer of Caucasian patients. Materials & methods: The incidence of cardiac …

Aim: Correct identification of RAS gene variants is key for targeted treatment decisions in
patients with metastatic colorectal cancer. Published RAS mutation rates differ and could be …

Introduction Body weight can affect exposure, safety and efficacy of antibody-based
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …

Актуальность. Рак толстой кишки-одно из самых распространенных злокачественных
новообразований в мире. При этом около 30% пациентов на момент постановки …

Background. Colon cancer is one of the most common malignancies worldwide. At the same
time, about 30% of patients at the time of diagnosis have a disseminated tumor process …